申请人:JANSSEN PHARMACEUTICA N.V.
公开号:EP0299566A2
公开(公告)日:1989-01-18
Novel N-(3-hydroxy-4-piperidinyl)substituted benzamides of formula
wherein:
R¹ is hydrogen, C₁₋₆alkyl, arylC₁₋₆alkyl, C₁₋₆alkylcarbonyl, aminoC₁₋₆alkyl or mono- and di(C₁₋₆alkyl)aminoC₁₋₆alkyl;
R² is hydrogen or C₁₋₆alkyl;
R³, R⁴ and R⁵ each independently are hydrogen, C₁₋₆alkyl, C₁₋₆alkyloxy, halo, hydroxy, cyano, nitro, amino, mono- and di(C₁₋₆alkyl)amino, aminocarbonyl, arylcarbonylamino, C₁₋₆alkylcarbonylamino, C₁₋₆alkylcarbonyl, C₁₋₆alkylcarbonyloxy, aminosulfonyl, C₁₋₆alkylaminosulfonyl, C₁₋₆alkylsulfinyl, C₁₋₆alkylsulfonyl, C₁₋₆alkylthio, mercapto, trifluoromethyl, arylC₁₋₆alkyloxy or aryloxy;
Alk is a C₁₋₆alkanediy;
X is O, S, NR⁶ C(=O) or C(=S);
Het is a five- or six membered heterocyclic ring being optionally fused with a six membered carbocyclic ring, and being optionally substituted;
the pharmaceutically acceptable acid addition salts and possible stereochemically isomeric forms thereof, which compounds are gastrointestinal motility stimulating agents; pharmaceutical compositions containing such compounds as an active ingredient and methods of preparing said compounds and pharmaceutical compositions.
式中的新型 N-(3-羟基-4-哌啶基)取代苯甲酰胺
其中
R¹ 是氢、C₁₋₆烷基、芳基C₁₋₆烷基、C₁₋₆烷基羰基、氨基C₁₋₆烷基或单-和二(C₁₋₆烷基)氨基C₁₋₆烷基;
R² 是氢或 C₁₋₆ 烷基;
R³、R⁴ 和 R⁵ 各自独立地为氢、C₁₋₆烷基、C₁₋₆烷氧基、卤代、羟基、氰基、硝基、氨基、一(C₁₋₆烷基)氨基和二(C₁₋₆烷基)氨基、氨基羰基、芳基羰基氨基、C₁₋₆烷基羰基氨基、C₁₋₆烷基羰基、C₁₋₆烷基羰基氧基、氨基磺酰基、C₁₋₆烷基氨基磺酰基、C₁₋₆烷基磺酰基、C₁₋₆烷硫基、巯基、三氟甲基、芳基₁₋₆烷氧基或芳基氧基;
Alk 是 C₁₋₆ 烷基;
X 是 O、S、NR⁶ C(=O) 或 C(=S);
Het 是五或六位杂环,可选择与六位碳环融合,并可选择被取代;
药学上可接受的酸加成盐及其可能的立体化学异构形式,这些化合物是胃肠道蠕动刺激剂;含有这些化合物作为活性成分的药物组合物以及制备所述化合物和药物组合物的方法。